ArticleJournal of global health2026
Global, regional, and national burden of epilepsy, 1990-2021: a Global Burden of Disease study.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epilepsy is a common neurological disorder characterised by spontaneous seizures without an identifiable cause, leading to high morbidity and a significant public health burden. Understanding trends in its incidence, prevalence, mortality, and disability-adjusted life years (DALYs) is essential for developing effective prevention and treatment strategies. We aim to describe global trends in epilepsy over the past 32 years and explore the impact of sociodemographic index (SDI) levels on disease burden using the Global Burden of Disease 2021 data. Methods: We analysed the global burden of epilepsy (1990-2019) using age-standardised rates (ASRs) and their 95% uncertainty intervals (UI). We assessed temporal trends with estimated annual percentage change and joinpoint regression. We used decomposition analysis to quantify the effects of population growth, ageing, and epidemiological shifts. Using the Pearson correlation, we examined the relationship between SDI and DALY rates. Additionally, we evaluated global disparities using the slope index of inequality and the concentration index. We used multidimensional health inequality analysis to identify the population with the highest disease burden. Lastly, we used frontier analysis to identify DALY gaps across 204 countries, and the Bayesian age-period-cohort model to predict future burden. Results: The global burden of epilepsy decreased from 1990 (ASR = 208.1; 95% UI = 163.2, 260.3) to 2021 (ASR = 177.8; 95% UI = 137.7, 225.9). However, there was a gradual increase in incidence from 1990 (ASR = 38.1; 95% UI = 27.9, 49.5) to 2021 (ASR = 42.8; 95% UI = 31.2, 53.7) and prevalence from 1990 (ASR = 287.5; 95% UI = 215.7, 363.0) to 2021 (ASR = 307.4; 95% UI = 234.7, 389.0). The ASR of DALYs was negatively correlated with SDI (R Conclusions: We provide valuable insights into global trends and the burden of epilepsy, emphasising the need for targeted prevention and healthcare strategies across socioeconomic levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.